Amir Valizadeh
he/him/his
Postdoctoral AssociateDownloadHi-Res Photo
Cards
Contact Info
Xu Lab
National Center for PTSD, Orange VA Clinic, 200 Edison Rd
Orange, CT 06477-3602
United States
Publications Overview
- 8 Publications
- 100 Citations
About
Titles
Postdoctoral Associate
Appointments
Psychiatry
Postdoctoral AssociatePrimary
Other Departments & Organizations
- Psychiatry
- Xu Lab
Education & Training
- Postdoctoral Research Fellow
- Tehran University of Medical Sciences (2022)
- Research Assistant
- Research Center for Molecular and Cellular Imaging (2020)
- MD
- Tehran University of Medical Sciences, Medicine (2019)
- Student Researcher
- Research Center for Immunodeficiencies (2018)
Research
Overview
Medical Research Interests
Artificial Intelligence; Epigenomics; Neurosciences; Psychiatry
ORCID
0000-0001-5983-8527- View Lab Website
Xu Lab
Research at a Glance
Publications Timeline
A big-picture view of Amir Valizadeh's research output by year.
8Publications
100Citations
Publications
2023
Automated diagnosis of autism with artificial intelligence: State of the art
Valizadeh A, Moassefi M, Nakhostin-Ansari A, Some’eh S, Hosseini-Asl H, Torbati M, Aghajani R, Ghorbani Z, Menbari-Oskouie I, Aghajani F, Mirzamohamadi A, Ghafouri M, Faghani S, Memari A. Automated diagnosis of autism with artificial intelligence: State of the art. Reviews In The Neurosciences 2023, 35: 141-163. PMID: 37678819, DOI: 10.1515/revneuro-2023-0050.Peer-Reviewed Original Research
2022
The mirror mechanism in schizophrenia: A systematic review and qualitative meta-analysis
Valizadeh A, Mbwogge M, Yazdi A, Amlashi N, Haadi A, Shayestefar M, Moassefi M. The mirror mechanism in schizophrenia: A systematic review and qualitative meta-analysis. Frontiers In Psychiatry 2022, 13: 884828. PMID: 36213922, PMCID: PMC9532849, DOI: 10.3389/fpsyt.2022.884828.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMirror neuron activityCortical motor systemSchizophrenia patientsMirror neuron systemUnderlying pathophysiologyCertainty of evidenceCase-control studyNew rehabilitation methodWeb of ScienceObjective assessment toolEligible studiesHealthy controlsVisuomotor neuronsPatientsNeuron activityPositive symptomsSystematic reviewInvestigation of heterogeneityMicrostructural integrityVote counting methodNeuron systemPathophysiologySymptomsFunctional integrityRehabilitation methodsThe safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial
Zarrabi M, Akbari M, Amanat M, Majmaa A, Moaiedi A, Montazerlotfelahi H, Nouri M, Hamidieh A, Badv R, Karimi H, Rabbani A, Mohebbi A, Rahimi-Dehgolan S, Rahimi R, Dehghan E, Vosough M, Abroun S, Shamsabadi F, Tavasoli A, Alizadeh H, Pak N, Zamani G, Mohammadi M, Javadzadeh M, Ghofrani M, Hassanpour S, Heidari M, Taghdiri M, Mohseni M, Noparast Z, Masoomi S, Goudarzi M, Mohamadpour M, Shodjaee R, Samimi S, Mohammad M, Gholami M, Vafaei N, Koochakzadeh L, Valizadeh A, Malamiri R, Ashrafi M. The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial. BMC Neurology 2022, 22: 123. PMID: 35351020, PMCID: PMC8966246, DOI: 10.1186/s12883-022-02636-y.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsUmbilical cord blood mononuclear cellsCord blood mononuclear cellsSpastic cerebral palsyBlood mononuclear cellsCerebral palsyHuman leukocyte antigenPosterior thalamic radiationUCB-MNCAdverse eventsFractional anisotropyMononuclear cellsCorticospinal tractWhite matter structuresMean changeDouble-blind sham-controlled clinical trialControl groupMean GMFM-66 scoresGross Motor Function MeasureSham-controlled clinical trialExperimental groupCommon adverse eventsDouble-blind studyMotor Function MeasureGMFM-66 scoresTrial registrationThe studyDisease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis
Valizadeh A, Fattahi M, Sadeghi M, Torbati M, Sahraian M, Azimi A. Disease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis. CNS Neuroscience & Therapeutics 2022, 28: 648-657. PMID: 35218155, PMCID: PMC8981477, DOI: 10.1111/cns.13815.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDisease-modifying therapiesCertainty of evidenceVolumes of T1Hypointense lesionsMultiple sclerosis patientsRisk of biasRoB 2 toolT1-hypointense lesionsRandom-effects modelEffects of FDANumber of lesionsAdult patientsSclerosis patientsMultiple sclerosisComparator groupPrognostic markerObjective markersSystematic reviewLesionsMean differenceMean volumePatientsRelevant studiesHypointenseTherapy
2021
Correlation between the clinical disability and T1 hypointense lesions’ volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta‐analysis
Valizadeh A, Moassefi M, Barati E, Sahraian M, Aghajani F, Fattahi M. Correlation between the clinical disability and T1 hypointense lesions’ volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta‐analysis. CNS Neuroscience & Therapeutics 2021, 27: 1268-1280. PMID: 34605190, PMCID: PMC8504532, DOI: 10.1111/cns.13734.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMean volumeCerebral magnetic resonance imagingPrognosis Studies toolMultiple sclerosis patientsRisk of biasT1-hypointense lesionsRandom-effects modelMagnetic resonance imagingWeb of ScienceClinical disabilityAdult patientsCerebral MRIEDSS scoreSclerosis patientsMultiple sclerosisDisability levelHypointense lesionsSystematic reviewResonance imagingPatientsRelevant studiesStudy toolCorrelation coefficientT1EDSSA placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury.
Shimia M, Iranmehr A, Valizadeh A, Mirzaei F, Namvar M, Rafiei E, Rahimi A, Khadivi A, Aeinfar K. A placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury. Journal Of Neurosurgical Sciences 2021, 67: 598-604. PMID: 34114429, DOI: 10.23736/s0390-5616.21.05266-8.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsGlasgow Outcome ScaleDisability Rating ScaleTraumatic brain injurySevere TBI patientsAmantadine hydrochlorideTBI patientsBrain injuryFunctional improvementClinical trialsSevere acute traumatic brain injuryAcute traumatic brain injuryMean Glasgow Outcome ScaleSevere traumatic brain injuryFunctional ability improvementEffect of amantadineDopaminergic neurotransmitter systemWeeks of trialAmantadine groupPharmacologic optionsDopamine agonistsOutcome ScaleNeurotransmitter systemsOutcome measurementsPatientsRating Scale
2019
Potential role of regulatory B cells in immunological diseases
Valizadeh A, Sanaei R, Rezaei N, Azizi G, Fekrvand S, Aghamohammadi A, Yazdani R. Potential role of regulatory B cells in immunological diseases. Immunology Letters 2019, 215: 48-59. PMID: 31442542, DOI: 10.1016/j.imlet.2019.08.004.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsRegulatory B cellsB cellsImmune systemChronic infectious diseasePotential therapeutic strategyMechanism of actionCytokine productionImmunomodulatory effectsPrimary immunodeficiencyTherapeutic strategiesImmunological diseasesTherapeutic effortsInfectious diseasesExact phenotypeDiseaseFindings of humanPotential roleBregsDiverse diseasesCellsCellular interactionsOngoing investigationAutoimmunityAllergyMalignancy
2017
Evaluation of infectious and non-infectious complications in patients with primary immunodeficiency
Bazregari S, Azizi G, Tavakol M, Asgardoon M, Kiaee F, Tavakolinia N, Valizadeh A, Abolhassani H, Aghamohammadi A. Evaluation of infectious and non-infectious complications in patients with primary immunodeficiency. Central European Journal Of Immunology 2017, 42: 336-341. PMID: 29479289, PMCID: PMC5820987, DOI: 10.5114/ceji.2017.72825.Peer-Reviewed Original ResearchCitationsConceptsNon-infectious complicationsPrimary immunodeficiency diseasesPID patientsCommon variable immunodeficiencyChronic granulomatous diseaseCVID patientsGenetic immune disordersMain infectious problemsNon-infectious manifestationsRetrospective cohort studyHyper-IgE syndromeVariety of complicationsHyper-IgM syndromeQuality of lifeInfectious complicationsNon-infectious problemsCohort studyCommon complicationDiagnostic delayAntibody deficiencyTroubling complicationVariable immunodeficiencyInfectious problemsOtitis mediaGranulomatous disease
Academic Achievements & Community Involvement
activity Student Headquarters Against COVID-19 at Tehran University of Medical Sciences
Public ServiceVice PresidentDetails2020 - 2020activity Internship Committee at Tehran University of Medical Sciences
CommitteesChairDetails2019 - 2020
Links
Related Links
Get In Touch
Contacts
Academic Office Number
Mailing Addresses
Xu Lab
National Center for PTSD, Orange VA Clinic, 200 Edison Rd
Orange, CT 06477-3602
United States
Xu Lab
Biomedical Informatics & Data Science, 100 College St, Fl 9
New Haven, CT 06510-3210
United States